Effectiveness of a School-centered Prevention Program on Prevalence of Latent Rheumatic Heart Disease

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age5-16
SponsorInsel Gruppe AG, University Hospital Bern

About this trial

The overall objective is to evaluate the effectiveness of a school-centered primary and secondary prevention program on the prevalence of latent rheumatic heart disease among schoolchildren in Nepal, and to investigate the role of socioeconomic and environmental factors in the development and progression of rheumatic heart disease.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age 5-16 years

Attending Tulsi Secondary Boarding School in Tulsipur, Nepal.

Disqualifiers

Children / primary caregivers not providing informed consent to participate

Children not attending Tulsi Secondary Boarding School in Tulsipur.

Trial design

Design model

Single group

Treatments tested in this trial

  • School nurse program

    Other intervention

    School nurse program providing health care through assessment, intervention and follow-up of group A β-hemolytic streptococcal pharyngitis and facilitation of secondary antibiotic prophylaxis for children with latent rheumatic heart disease.

Treatment groups

2,300 Participants
are divided into 1 treatment group
Group A: Experimental: Implementation of a dedicated school nurse programExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Prevalence of definite or borderline Rheumatic Heart Disease

Prevalence of definite or borderline Rheumatic Heart Disease according to the criteria of the World Heart Federation as assessed by systematic echocardiographic screening

Time frame
4 years

Secondary outcomes

1

Group A β-hemolytic streptococcal pharyngitis

Number of patients with group A β-hemolytic streptococcal pharyngitis within study participation

Time frame
4 years
2

Acute rheumatic fever

Number of patients with acute rheumatic fever within study participation

Time frame
4 years
3

Rheumatic heart disease

Number of patients with rheumatic heart disease within study participation

Time frame
4 years
4

Adverse reactions to penicillin injections

Number of patients with adverse reactions to penicillin injections within study participation

Time frame
4 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.